Inozyme Pharma (NASDAQ:INZY) Downgraded to “Hold” Rating by Wedbush

Inozyme Pharma (NASDAQ:INZY) was downgraded by analysts at Wedbush from a “strong-buy” rating to a “hold” rating in a report released on Friday,Zacks.com reports. Wedbush also issued estimates for Inozyme Pharma’s Q2 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.23) EPS, Q1 2026 earnings at ($0.25) EPS, Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($1.00) EPS and FY2027 earnings at ($0.79) EPS.

INZY has been the subject of several other reports. Jefferies Financial Group reissued a “hold” rating and issued a $4.00 price target (down from $15.00) on shares of Inozyme Pharma in a report on Friday. Piper Sandler cut their price target on shares of Inozyme Pharma from $30.00 to $23.00 and set an “overweight” rating for the company in a report on Tuesday, March 11th. Needham & Company LLC downgraded shares of Inozyme Pharma from a “moderate buy” rating to a “hold” rating in a report on Friday. Wells Fargo & Company reissued an “equal weight” rating and issued a $4.00 price target on shares of Inozyme Pharma in a report on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Inozyme Pharma in a report on Thursday, April 10th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $11.75.

Inozyme Pharma Stock Up 178.2%

Shares of NASDAQ:INZY opened at $3.95 on Friday. The firm has a fifty day moving average price of $1.09 and a two-hundred day moving average price of $1.89. The company has a debt-to-equity ratio of 0.51, a current ratio of 7.68 and a quick ratio of 7.68. Inozyme Pharma has a one year low of $0.72 and a one year high of $6.24. The company has a market cap of $255.02 million, a price-to-earnings ratio of -2.53 and a beta of 1.35.

Inozyme Pharma (NASDAQ:INZY) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.01). Analysts anticipate that Inozyme Pharma will post -1.59 EPS for the current fiscal year.

Institutional Trading of Inozyme Pharma

A number of hedge funds have recently made changes to their positions in INZY. JPMorgan Chase & Co. raised its position in Inozyme Pharma by 31.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 28,928 shares of the company’s stock worth $151,000 after purchasing an additional 6,851 shares during the period. Palumbo Wealth Management LLC raised its position in Inozyme Pharma by 52.3% in the 4th quarter. Palumbo Wealth Management LLC now owns 23,281 shares of the company’s stock worth $64,000 after purchasing an additional 7,995 shares during the period. American Century Companies Inc. raised its position in Inozyme Pharma by 11.6% in the 4th quarter. American Century Companies Inc. now owns 79,349 shares of the company’s stock worth $220,000 after purchasing an additional 8,263 shares during the period. Geode Capital Management LLC raised its position in Inozyme Pharma by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 1,179,622 shares of the company’s stock worth $3,268,000 after purchasing an additional 8,450 shares during the period. Finally, Deutsche Bank AG raised its position in Inozyme Pharma by 29.1% in the 4th quarter. Deutsche Bank AG now owns 40,215 shares of the company’s stock worth $111,000 after purchasing an additional 9,055 shares during the period. 88.30% of the stock is owned by institutional investors.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.